Established in Ankleshwar in the year 1996, “Tatwa Chintan Pharma Chem Pvt. Ltd ”is noted as a notable manufacturer and supplier of a broad assortment of hydroxides, specialty chemicals, methylating agents, electrolyte chemicals, pyridinium salts and many more. Tatva Chintan Pharma Chem IPO will hit the market in 16 July 2021.
Table of Contents
About Company
They are a private limited firm, acting as a leading organization in this domain since its inception. These chemicals are processed using superior quality compounds and the latest technology under the direction of experienced chemical experts.
The chemicals offered are highly demanding for their characteristics such as longer shelf life, precise formulation, moisture-proof packaging, etc. They offer these chemicals in several packaging options to meet the exact needs of their reputed clients.
Due to their ethical business policies, client oriented approach and competitive pricing structure; they are continuously expanding their market share.
Plant
They have developed a state-of-the-art art infrastructure unit spread over a vast area of land. To complete the smooth and orderly work flow, they have divided they infrastructure into several sub-parts such as procurement, processing, packaging, quality testing, research and development and so on.
They processing unit is equipped with modern machinery based on modern technologies. They infrastructural unit provides us the facility to meet the vast and urgent needs of our patrons within the committed time period.
Management Team
In addition, the components they use in processing are prepared under the guidance of their experienced procurement officers. Works in close coordination with each other, their experts are highly enthusiastic and committed to the growth of our firm.
They are working under the guidance of their mentor “Shekhar Somani”. He have inspired them to work according to the norms and standards of the industry. Their strength lies in: customers, innovation, integrity, people and performance.
Mission
Their mission is to keep clients at the heart of everything they do, and this is achieved through client focus, personal and organizational leadership, and a process of excellence.
Tatva Chintan Pharma Chem IPO Issue
Tatva Chintan Pharma, headquartered in Gujarat has submitted Draft Red Herring Prospectus(DRHP) to Securities and Exchange Board of India(SEBI) for initial public offering (IPO) of INR 450 crore on 31 March, 2021.
They planned to collect INR 450 cr via its initial public offering (IPO). There is a fresh issue of 225 cr. and offer for sale is around 225 cr. vaule Equity Shares mentioned in the drhp of the company.
They got approval from Securities and Exchange Board of India(SEBI) on 05 July, 2021 to float the initial public offering (IPO) in the market.
Financials Trends
| Particulars | For the year/period ended ( in Cr.) | ||||
|---|---|---|---|---|---|
| 31-Dec-20 | 31-Mar-20 | 31-Mar-19 | 31-Mar-18 | ||
| Total Assets | 275.99 | 248.94 | 187.51 | 143.72 | |
| Total Revenue | 195.03 | 264.62 | 206.80 | 137.29 | |
| Profit After Tax | 31.14 | 37.79 | 20.54 | 12.29 | |
Basic and Diluted Earnings Per Share (EPS)
| Financial Period | Basic EPS (in INR) | Diluted EPS (in INR) | Weight |
| Financial Year 2020 | 18.81 | 18.81 | 3 |
| Financial Year 2019 | 10.23 | 10.23 | 2 |
| Financial Year 2018 | 6.12 | 6.12 | 1 |
| Weighted Average | 13.84 | 13.84 | |
| (9 months) Dec. 31, 2020 | 15.50 | 15.50 | – |
Objects of the Issue
- Prepayment / repayment of all or a portion of the outstanding borrowings of the company to be availed on consolidated basis.
- To meet common corporate objectives.
Basis of the offer
The following are some of the qualitative considerations and our strengths that go into determining the Offer Price:
- With constant quality, we are a major supplier of structure guiding agents and phase transfer catalysts.
- With a strong client base across multiple industries and significant entry barriers, the company has a global presence.
- A wide specialised product portfolio that demands a high level of technical expertise
- Advanced production facilities with a priority on chemical methods that are “green.”
- R&D capabilities are robust.
- Promoters with deep knowledge and a solid management team.
- Excellent financial results.
Tatva Chintan Pharma Chem IPO Peer Comparison
| S. No. | Company Name | PE |
| 1 | Aarti Industries Limited | 41.85 |
| 2 | Navin Fluorine International limited | 30.91 |
| 3 | Alkyl Amines chemicals limited | 59.29 |
| 4 | Vinati Organics Limited | 44.11 |
| 5 | Fine Organic Industries Limited | 41.72 |
IPO Tentative Details
| IPO Opening Date | 16 July 2021 |
| IPO Closing Date | 20 July 2021 |
| Issue Type | Book Built |
| Face Value | 10 per share |
| IPO Price | 1073 to 1083 per equity share |
| Market Lot | 13 |
| Min Order Quantity | 13 |
| Listing At | BSE, NSE |
| Issue Size | 450 cr. |
| Fresh Issue | 225 cr. |
| Offer for Sale | 225 cr. |
IPO Tentative Date
Tatva Chintan Pharma Chem IPO open date is 16 July 2021, and the closing date is 20 July 2021. The issue may list on 29 July 2021.
| IPO Open Date | 16 July 2021 |
| IPO Close Date | 20 July 2021 |
| Basis of Allotment Date | 26 July 2021 |
| Initiation of Refunds | 27 July 2021 |
| Credit of Shares to Demat Account | 28 July 2021 |
| IPO Listing Date | 29 July 2021 |
Basis of Allotment
| Type | % of Offer | Basis of Allotment |
|---|---|---|
| Qualified Institutional Buyer | 50 |
Roughly
equivalent
|
| Non Institutional Investor | 15 |
Roughly
equivalent
|
| Retail | 35 | Minimum level of 1 lot, based on availability, for every shareholder. |
Tatva Chintan IPO Allotment Status
Allotment of equity stocks subject to the Fresh Issue and transfer of the Promoter Selling Shareholders’ OFS Stocks to the winning Bidders subject to the Offer for Sale. Nevertheless, the status of the allotment has yet to be revealed.
Here, you can find the Allotment Status of Tatva Chintan IPO.
Tatva Chintan IPO gmp (Tatva Chintan Pharma Chem IPO gmp)
Tatva Chintan IPO Grey market premium is as follows and you can check GMP of other IPOs as well from links given below:
| Date | GMP (in Rs) | Subject to Sauda | Kostak (in Rs) |
| 28 July 2021 | 1100 | 4500 | 550 |
| 27 July 2021 | 1175 | 2500 | 250 |
| 26 July 2021 | 1075 | 4200 | 450 |
| 25 July 2021 | 999 | 3600 | 550 |
| 24 July 2021 | 995 | 3300 | 400 |
| 23 July 2021 | 985 | 2700 | 300 |
| 22 July 2021 | 965 | 2900 | 350 |
| 21 July 2021 | 920 | 5500 | 700 |
| 20 July 2021 | 765 | 4200 | 650 |
| 19 July 2021 | 738 | 3200 | 450 |
| 18 July 2021 | 725 | 1800 | 250 |
| 17 July 2021 | 705 | 4500 | 500 |
| 16 July 2021 | 658 | 3500 | 550 |
| 15 July 2021 | 633 | 2800 | 400 |
| 14 July 2021 | 589 | 2500 | 350 |
| 13 July 2021 | 605 | ||
| 12 July 2021 | 595 | ||
| 11 July 2021 | 590 | ||
| 10 July 2021 | 580 |
Check Out The GMP Of other IPOs
Tatva Chintan Pharma Chem IPO Review
You can apply for Listing gain & long Term as well without any issues. There is great possibilities of growth in their industry.
Tatva Chintan IPO Risk
- The continued impact of the COVID-19 epidemic might have a substantial influence on their operations, as well as their company and income.
- Manufacturing operations that experience unplanned slowdowns or shutdowns might have a negative impact on their company and financial situation.
- Their institutional customers hold us to high quality standards, technical specifications, and audits. Their reputation might be harmed if they do not meet the quality requirements and technological specifications.
- An increase in the cost of raw materials might have a significant negative impact on their operating performance and financial position.
Other Threats
- Their buisness exposes them to dangers in a number of nations that might have a significant negative impact on their business and prospects.
- Their management has complete control over how the revenues of the Offer are used. Any change in how their Net Proceeds are used would be subject to various regulatory requirements, including shareholder approval.
- For some raw materials, they rely on a small number of suppliers. The loss of one or more of these suppliers might have a negative impact on their business and operations.
- Their production plants are located in a single location, and any negative developments in that region might have a negative impact on their company and operating performance.
Tatva Chintan Pharma Chem IPO Brokerage views
- Yes Securities : Subscribe
- Choice Brokering: Subscribe
- Axis Securities: Subscribe
- IIFL Securities: Subscribe
- Trade swift: Subscribe
- Anand Rathi : Subscribe
- ICICI Securities: Subscribe
Tatva Chintan Pharma Chem IPO Subscription Status
| Date | Day | QIB | NII | Retail | Employees | Total Subscription |
| 16 July 2021 | 1 | 0.51 | 1.15 | 8.32 | N/A | 4.55 |
| 19 July 2021 | 2 | 1.98 | 12.32 | 23.96 | N/A | 15.19 |
| 20 July 2021 | 3 | 187 | 517 | 35.68 | N/A | 182 |
Promoters
- Ajaykumar Mansukhalal Patel
- Chintan Nitinkumar Shah
- Shekhar Rasiklal Somani
Promoter Holding
| Pre Issue Share Holding | 81.08% |
| Post Issue Share Holding |
Tatva Chintan Pharma Chem IPO Prospectus
Contact Details
Tatva Chintan Pharma Chem Private Limited
Plot No. 502 / 17, GIDC Estate, Ankleshwar,
Bharuch, Gujarat – 393 002, India;
Tel: +91 75730 46951 / +91 75730 46952
E-mail: [email protected]
Website: https://www.tatvachintan.com/
Registrar
Link Intime India Private Ltd
Link Intime India Private Ltd
C 101, 247 Park, L.B.S.Marg,
Vikhroli (West), Mumbai – 400083
Phone: +91-22-4918 6270
Email: [email protected]
Website: http://www.linkintime.co.in
Lead Manager(s)
- ICICI Securities Limited
- JM Financial Limited
We hope we are able to answer all your questions about Tatva Chintan Pharma Chem IPO. If you don’t have a Demat account, open it now with Zerodha best trading app.
Clarification
The reference of IPO Grey Market Premium (IPO GMP) is only valid for the date specified in the header.
On the IPO Grey Market, we do not purchase or sell IPO forms.
The Kostak Rate is the profit earned by selling an IPO application (in an off-market transaction) to somebody else before the issue is allotted or listed.
Do not subscribe to an IPO based solely on the premium price, as it may alter at any time before to the listing. Only consider the fundamentals of the companies when subscribing.
The GMP rates for IPOs are based on market intelligence. Please keep in mind that these IPO GMP rates may vary by geography and market.
Note:
We do not engage in grey market trading or facilitate the purchase or sale of IPO forms.
What is Grey Market?
The phrase “grey market” refers to an illegal over-the-counter market where IPO applications and IPO stock are traded before the entity is listed on a stock exchange. This is a technique for dealers to help consumers who wish to sell their home before it goes on the market.
This is also a way to increase the listing fee and provide help for the issue prior to the listing. In the IPO grey market, there are two types of transactions that take place:
- IPO stocks are traded at a premium in the grey market.
- At a kostak, an IPO application is traded.
What is grey Market Premium?
The Grey Market Premium, or GMP, is the price at which IPO stock shares are exchanged in the grey market.
This could be correct or incorrect, implying that the grey market trading price is greater or cheaper than the issue price, depending on demand and supply for the stocks.
Typically, individuals who do not want to incur the risk of their shares not being allocated through an IPO can purchase shares on the grey market in the hopes of flipping them on the IPO for a profit.
What is Kostak?
The additional amount in rupees at which IPO applications are sold in the IPO Grey Market is known as kostak (or price of application). The bonus of a maximum lot retail application in an IPO is generally described as the ‘Kostak’ value.
The Kostak price is significant primarily before the offer is closed for subscription and the ultimate bidding status is made accessible to IPO participants. After the final auction status is known to investors, only a small percentage of IPO applications are exchanged.
‘Kostak’ is made for those who do not want to incur a risk on an IPO or gain from a listing.
Example:
Tatva Chintan IPO
Issue Price: Rs 306 Per Equity Share (Maximum Bid price)
Lot Size: 45
Grey Market Premium: Rs 220 to Rs 230
Kostak (Rs 13770): Rs 680 to Rs 720
This means Tatva Chintan IPO applications of Rs 13770 are being traded in IPO Grey Market at Rs 680 to Rs 720.
Despite the fact that this IPO’s Grey Market Premium is roughly 75% of the issue price, the ‘Kostak’ is just 5% of the application value.
Kostak rate
The Kostak rate is the fee received by an investor who sells his or her IPO application on the grey market. Regardless of allotment status, this is the money an individual stands to gain.
Subject to Sauda
The money that an investor stands to gain by selling his or her application for firm allotment is referred to as the subject to Sauda. Firm allocation is the important operative phrase here. The sauda will be cancelled if the applicant is not allotted.
When selling an IPO application in the grey market, the client and seller agree that the sale will only be legal if the seller receives the allocation. The deal is avoided if the seller does not get any stocks throughout the IPO procedure.
FAQ
Tatva Chintan Pharma Chem IPO Opening Date?
Tatva Chintan Pharma Chem IPO will open 0n 16 July 2021.
Tatva Chintan Pharma Chem IPO Listing Date?
Tatva Chintan Pharma Chem IPO will list is 29 July 2021.
Tatva Chintan Pharma Chem IPO GMP Today?
Tatva Chintan Pharma Chem IPO Grey Market Premium is INR 1175.
Tatva Chintan Pharma Chem IPO Allotment Date?
Tatva Chintan Pharma Chem IPO basis of allotment will be 0n 26 July 2021.
Lot size for Tatva Chintan Pharma Chem IPO?
Lot size for Tatva Chintan Pharma Chem IPO is 13.
Visitor Rating: 5 Stars
Visitor Rating: 4 Stars
Visitor Rating: 5 Stars
Visitor Rating: 1 Stars
Visitor Rating: 1 Stars